- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04689191
III фаза клинических испытаний менингококковой полисахаридной вакцины групп А и С
Рандомизированное, двойное слепое, контролируемое исследование III фазы менингококковой полисахаридной вакцины группы А и С у здоровых детей в возрасте 2–6 лет, не меньшая эффективность
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.
Обзор исследования
Статус
Условия
Подробное описание
This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Yunnan
-
Kunming, Yunnan, Китай
- Yunnan Center for Disease Control and Prevention
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
-
The First stage study (An early safety assessment study):
-
18-50 years group:
-
Inclusion Criteria:
- Healthy adults aged 18 to 50 years.
- Proven legal identity.
- Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- Immunization with any vaccine within 30 days.
- Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
- Any other situations judged by investigators as not suitable for participating in this study.
-
-
7-17 years group:
-
Inclusion Criteria
- Healthy volunteer aged 7 to 17 years.
- Proven legal identity.
- Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- Immunization with any vaccine within 30 days.
- Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Women with positive pregnancy test after menarche.
- Any other situations judged by investigators as not suitable for participating in this study.
-
-
2-6 years group:
-
Inclusion Criteria
- Healthy children aged 2 to 6 years.
- Proven legal identity.
- Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
- Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Any other situations judged by investigators as not suitable for participating in this study.
-
The Second stage study (A phase III clinical trial )
-
Inclusion Criteria
- Healthy children aged 2 to 6 years.
- Proven legal identity.
- Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
- Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Any other situations judged by investigators as not suitable for participating in this study.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Experimental Vaccine
One dose of Experimental Group A and C meningococcal polysaccharide vaccine |
One dose of Experimental Group A and C meningococcal polysaccharide vaccine |
|
Активный компаратор: Active Comparator Vaccine
One dose of Control Group A and C meningococcal polysaccharide vaccine |
One dose of Control Group A and C meningococcal polysaccharide vaccine |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Seroconversion rate of Group A meningococcal bactericidal antibody
Временное ограничение: 28 days after vaccination
|
Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination |
28 days after vaccination
|
|
Seroconversion rate of Group C meningococcal bactericidal antibody
Временное ограничение: 28 days after vaccination
|
Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination |
28 days after vaccination
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Adverse reactions/events rate
Временное ограничение: 7 days after vaccination
|
Occurence of adverse reactions/events after vaccination |
7 days after vaccination
|
|
Adverse reactions/events rate
Временное ограничение: 28 days after vaccination
|
Occurence of adverse reactions/events after vaccination |
28 days after vaccination
|
|
Serious adverse events
Временное ограничение: 6 months after the second vaccination
|
Occurence of Serious adverse events after vaccination |
6 months after the second vaccination
|
|
GMT of Group A meningococcal bactericidal antibody
Временное ограничение: 28 days after the second vaccination
|
GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination |
28 days after the second vaccination
|
|
GMT of Group C meningococcal bactericidal antibody
Временное ограничение: 28 days after the second vaccination
|
GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination |
28 days after the second vaccination
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
GMT of IgG antibody against Hepatitis A
Временное ограничение: 28 days after the second vaccination
|
GMT of IgG antibody against Hepatitis A at day 28 after vaccination |
28 days after the second vaccination
|
|
Seropositive rate of IgG antibody against Hepatitis A
Временное ограничение: 28 days after the second vaccination
|
Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination |
28 days after the second vaccination
|
Соавторы и исследователи
Следователи
- Главный следователь: Yan Zheng, Mater, Yunnan Center for Disease Control and Prevention
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Нейровоспалительные заболевания
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Инфекции
- Бактериальные инфекции
- Бактериальные инфекции и микозы
- Грамотрицательные бактериальные инфекции
- Инфекции центральной нервной системы
- Нейссериевые инфекции
- Менингит
- Менингит, Бактериальный
- Бактериальные инфекции центральной нервной системы
- Менингококковые инфекции
- Менингит, менингококковая
Другие идентификационные номера исследования
- 20190702
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .